INO241220P9000
- 0.00
- 0.000.00%
Inovio Pharmaceuticals Newsroom
Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
Top Midday Decliners
Inovio Pharmaceuticals Shares Touch 52-Week Low After $30M Offering
Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast
US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings
Why Inovio Pharmaceuticals (INO) Stock Is Down 40%
Wall Street Set to Open Higher Friday as Investors Shake Off Bad Week
Investors Look to End Week on Strong Note as US Futures Rise in Friday's Premarket
Inovio Pharmaceuticals Priced An Underwritten Public Offering Of 10M Shares And Accompanying Warrants To Purchase 10M Shares At An Exercise Price Of $3.76/Share, At A Combined Public Offering Price Of $3/Share And Accompanying Warrant, With Gross...
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
RH, Broadcom And 3 Stocks To Watch Heading Into Friday
Inovio Down 20% After Hours on Planned Stock and Warrant Sale
Express News | Inovio Announces Proposed Public Offering
INOVIO Announces Proposed Public Offering
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
Inovio Pharmaceuticals' INO-3107 Shows Promising Clinical Trial Results, Earns 'Buy' Rating From Analyst
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)